← Leaderboards
Lynn Misel
Pharmacology Discovery Services Taiwan, Ltd.
$434,483
Attributed
$434,483
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $385.7K · FY2020–21$500K$375K$250K$125K$0
'20
'21
Funding mix
By agency
NIH$434,483 · 1
By mechanism
N01$434,483 · 1
Top collaborators
No co-investigators on record.
Most similar at Pharmacology Discovery Services Taiwan, Ltd.
Same institution · by research overlap
- Lynn Miesel$3,721,895
- Anthony Gallacher$2,462,993
- Lyne Miesel$950,904
Others in their field
Other Emerging Leaders on “Acinetobacter”
- Keith Kaye · University Of Michigan At Ann Arbor$11,130,173
- Jurgen Bernd Bulitta · State University Of New York At Buffalo$10,686,622
- Ryan Cirz · Revagenix, Inc.$6,642,016
- Tony Velkov · Monash University$4,710,060
- Patrick R Secor · University Of Montana$4,394,600
- Steven Armen Boyd · Venatorx Pharmaceuticals, Inc.$4,265,587
Research focus
AcinetobacterAnimal ModelAnimal Model DevelopmentAntimicrobial ResistanceBacteremiaContractsEfficacy TestingEscherichia ColiInfectious Disease ModelKlebsiellaLicensureLung InfectionsMouse ModelPeritonitisPseudomonasPseudomonas AeruginosaStandardizationStaphylococcus AureusTherapeutic Evaluation
Grant awards (2)
Task A41: Therapeutic Testing in Murine Models of Pseudomonas Lung Infection and Murine Models of Bacteremia and Peritonitis$48,801
N01 · FY2021 · AI · contact PI
Task A41: Therapeutic Testing in Murine Models of Pseudomonas Lung Infection and Murine Models of Bacteremia and Peritonitis$385,682
N01 · FY2020 · AI · contact PI